BACKGROUND Somatic mutations accumulate in normal tissues as a function of time. The
great majority of these mutations have no effect on fitness, so selection does not act upon …

Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …

The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds
90% when diagnosed after age 65. Most cases arise without any detectable early symptoms …

Age-related diseases are frequently linked to pathological immune dysfunction, including
excessive inflammation, autoreactivity and immunodeficiency. Recent analyses of human …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …

Clonal hematopoiesis (CH) arises when a substantial proportion of mature blood cells is
derived from a single dominant hematopoietic stem cell lineage. Somatic mutations in …

Patients with acute myeloid leukemia (AML) have conventionally received more intense
therapy than patients with myelodysplastic syndrome (MDS). Although less intense …

We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly
selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with …